



Nemolizumab in Moderate-to-Severe Atopic Dermatitis: Long-Term Safety and Efficacy and New Biomarker Insights

A summary of selected data presented at the European Academy of Dermatology and Venereology (EADV) Congress held in Amsterdam, the Netherlands, from 24th–28th September 2024.

Presenters:	Diamant Thaçi, ¹ Emma Guttman-Yassky ²
	<ol style="list-style-type: none"> 1. Institute and Comprehensive Centre for Inflammatory Medicine, University of Lübeck, Germany 2. Icahn School of Medicine at Mount Sinai, New York, USA
Disclosure:	Thaçi is a lecturer and/or consultant for AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Janssen-Cilag, Kyowa Kirin, Leo Pharma, L'Oréal, Eli Lilly, Novartis, Pfizer, Regeneron, Sanofi, Target RWE, and UCB; and has received grants from AbbVie, Leo Pharma, and Novartis (paid to institution). Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, Galderma, Celgene, Leo Pharma, Janssen, Medimmune, Dermira, Anacor, AnaptysBio, Glenmark, Novartis, Abbvie, GSK, Sun Pharma, Mitsubishi Tanabe, Vitae, Almirall, Asana Biosciences, Amgen, Immune, Gilead, Concert, Kyowa Kirin, DS Biopharma, Ralexar, Eli Lilly, UCB, Escalier, Boehringer, Botanix, Incyte, Sienna, Innovaderm, Cara Therapeutics, Dermavant, Union Therapeutics, Kiniksa, Arena, FLX Bio, and Target.
Acknowledgements:	Writing assistance was provided by Helen Boreham, Wetherby, UK.
Keywords:	Atopic dermatitis, biomarker, itch, long-term, nemolizumab, skin inflammation, quality of life (QoL).
Citation:	EMJ Dermatol. 2025;13[Suppl 1]:2-8. https://doi.org/10.33590/emjdermatol/WMSU2984
Support:	The publication of this article was supported by Galderma.



Meeting Summary

Nemolizumab is an anti-IL-31R α monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and ARCADIA-2) in adults and adolescents with moderate-to-severe atopic dermatitis (AD). This article summarises selected data from oral presentations on nemolizumab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting held in September 2024 in Amsterdam, the Netherlands.

Data from interim analyses were presented from the ARCADIA open-label extension study that evaluated the long-term safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe AD. These first long-term data on nemolizumab

treatment showed continuous improvement up to 56 weeks in key signs and symptoms of AD, as well as patient-reported quality of life (QoL) measures. Safety findings were consistent with those previously reported, further supporting the long-term use of nemolizumab. Maintaining long-term efficacy and safety over extended periods of treatment is crucial in the management of chronic skin diseases, such as AD, which impose a substantial patient burden.

The second presentation demonstrated how clinical improvements in signs and symptoms of AD with nemolizumab treatment correlate with a notable impact on pruritus and hyperplasia/fibrosis biomarkers in the skin. Tape-strips transcriptomic analysis was used to evaluate the effect of nemolizumab on gene expression in a subset of patients with AD from the ARCADIA 1 and 2 studies. Results showed that nemolizumab robustly modulates gene expression, acting on biomarkers related to the three key pillars of AD pathogenesis: pruritus, inflammation, and skin barrier dysfunction. Importantly, patients with severe pruritus at baseline showed stronger downregulation of inflammatory markers, including Type 2, Type 17, and Type 1 biomarkers, highlighting nemolizumab's therapeutic potential in patients with AD extensively affected by itch.

Introduction

AD is a common, chronic, inflammatory skin condition that requires long-term treatment.^{1,2} The hallmark clinical symptom of AD is pruritus (itch), which significantly impacts patients' QoL.³

Nemolizumab is an IL-31R α antagonist that inhibits the binding of IL-31, a neuroimmune cytokine and key mediator for itch in AD, to its receptor.⁴⁻⁶ IL-31 signals through a heterodimeric receptor composed of OSMR β and IL-31R α , triggering itch, skin barrier disruption, and exacerbation of inflammation, and is strongly implicated in the pathogenesis of AD.⁶⁻⁸

Nemolizumab was evaluated in two global Phase III studies, ARCADIA-1 (NCT03985943) and ARCADIA-2 (NCT03989349), in adults and adolescents with moderate-to-severe AD, in which it provided clinically meaningful improvements in itch, skin lesions, and sleep at Week 16 and responses were sustained up to Week 48.⁹

Nemolizumab Long-Term Safety and Efficacy up to 56 weeks in the ARCADIA Open-Label Extension Study in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis

Diamant Thaçi from the Institute and Comprehensive Centre for Inflammatory Medicine, University of Lübeck, Germany, presented interim data up to 56 weeks from the ARCADIA long-term extension study, which aimed to evaluate the long-term safety and efficacy of nemolizumab up to 200 weeks in patients aged ≥ 12 years with moderate-to-severe AD.¹⁰

The population for this prospective, multicentre, open-label, long-term extension (LTE) study (NCT03989206) consisted of patients from lead-in Phase II/IIb and Phase III/IIIb studies (including the ARCADIA 1 and 2 trials), as well as newly recruited adolescents.¹¹ As Thaçi explained, this resulted in a heterogeneous baseline patient population. Patients received 30 mg subcutaneous nemolizumab every 4 weeks up to Week 200 on a background of low/medium potency topical corticosteroids with or without topical calcineurin inhibitors.

Data from patients in the LTE were analysed according to the treatment received in the lead-in studies: those with previous nemolizumab experience (PNE; n=962) and those who were nemolizumab naïve (NN; n=536). A total of 723 patients (41.6%) had completed Week 56 at the data cut-off (September 30 2022). The overall discontinuation rate for the PNE and NN cohorts in the LTE study was 21.6% and 25.3%, respectively, with the main reason for discontinuing treatment being patients' own request.


Thaçi presented data as observed from evaluable patients at each time point up to 56 weeks in the nemolizumab LTE study across a variety of key AD efficacy outcome measures. Ongoing and clinically meaningful improvements in skin lesions were observed through Week 56 as measured by an Investigator's Global Assessment (IGA) score of 0/1 (clear/almost clear) and Eczema

Area and Severity Index (EASI) 75 scores. Notably, the response to treatment in the NN group also converged to treatment response in the PNE group over 56 weeks.

At Week 56, 47% and 49% of PNE and NN evaluable patients achieved IGA 0/1, respectively, with long-term nemolizumab treatment, from baseline levels of 29% and 18%. Similarly, the proportion of PNE and NN evaluable patients attaining EASI-75 increased from 38% and 24%, respectively, at baseline to 73% and 79% after 56 weeks of nemolizumab treatment (Figure 1).

Moreover, improvements in itch and sleep were observed over time with long-term nemolizumab treatment as measured by changes in the SCORing Atopic Dermatitis (SCORAD) score, including itch and sleep visual analogue scale (VAS) components (Figure 1).

Figure 1: Proportion of evaluable patients with IGA score of 0/1 and EASI-75 up to 56 weeks.



Analysis was conducted in safety population, defined as patients who received at least one dose of the study drug. The endpoint was summarised using observed cases (OC analysis). LTE baseline is the last available measurement prior to the first treatment in this study.

EASI: Eczema Area and Severity Index; EASI-75: 75% improvement in EASI from lead-in baseline; IGA: Investigator's Global Assessment; LTE: long-term extension; N: total number of patients in the safety population; n: number of patients with available data; NN: nemolizumab-naïve; PNE: previous nemolizumab experience; SCORAD: SCORing Atopic Dermatitis; VAS: visual analogue scale.

SCORAD Pruritus VAS improved by approximately 75% and SCORAD Sleep Loss VAS by about 70%, versus lead-in baseline, in both NN and PNE groups after 56 weeks of treatment.

In addition, patient-reported outcomes such as QoL, as measured by the Dermatology Life Quality Index (DLQI), continued to improve over 56 weeks of nemolizumab treatment. Overall, 86% of PNE and 90% of NN evaluable patients experienced a ≥ 4 point reduction in DLQI by Week 56, from LTE baselines of 77% and 63%, respectively. The proportion of evaluable patients achieving DLQI 0/1 at Week 56 was 38% and 43% in the PNE and NN cohorts, respectively, compared to LTE baselines of 27% and 14%.

Safety data from the ARCADIA LTE study were reassuring and supported the long-term use of nemolizumab for the treatment of adolescent and adult patients with moderate-to-severe AD. Adverse events (AE) were consistent with those previously reported (Table 1).¹⁰ COVID-19 and AD were the most common treatment-emergent AEs (TEAE) occurring in $\geq 5\%$ of patients.

Overall, Thaçi concluded that these data from interim analysis of the ARCADIA LTE study support the long-term safety and efficacy of nemolizumab in patients with moderate-to-severe AD. Nemolizumab proved well-tolerated up to Week 56, and clinically meaningful improvements in AD signs and symptoms were observed with continuous treatment.

Tape-Strips Transcriptomic Analysis of Patients with Moderate-to-Severe AD Treated with Nemolizumab

Emma Guttman-Yassky from the Icahn School of Medicine at Mount Sinai, New York, USA, presented results from a biomarker sub-study that used tape-stripping to evaluate the effect of nemolizumab on the cutaneous transcriptomic profile in a subset of AD patients from the ARCADIA 1 and 2 studies.¹²

Tape-strips transcriptomic analysis, a minimally invasive method that provides a detailed molecular profile of the skin affected by AD,¹³ was used to study gene expression changes before and after treatment with nemolizumab.¹² A total of 72 patients were treated with nemolizumab and 39 with placebo, and they were evaluated at baseline and after 16 weeks. No significant differences were observed between the two groups in terms of demographics or baseline characteristics. Tape-strips were collected from lesional and non-lesional skin of these patients. Transcriptomic analysis revealed significant gene changes during nemolizumab treatment. Notably, nemolizumab showed robust modulation of biomarkers of pruritus (e.g., *TRPM1*, *TRPV3*, and *OSMR*) and hyperplasia/fibrosis (e.g., *KRT6C*, *SERPINB*, *COL1A1*, *COL12A1*, *IGFBP3*, and *SOX9*). Nemolizumab also downregulated key immune markers, demonstrating improvement in both Th17/Th22 (*S100A7*, *S100A8*, *S100A9*, *S100A12*, *IL36G*, and *PI3*) and Th1 markers (e.g., *CCL2*, *MX1*, and *OASL*) across all patients.

Analysis of a subset of nemolizumab-treated patients with severe baseline pruritus (Peak Pruritus Numerical Rating Scale [PPNRS] >7) showed greater Th1, Th2, Th22/IL22, and Th17 immune activation at baseline and more robust immune downregulation upon nemolizumab treatment at Week 16 than in those treated with placebo. Specifically, patients with more severe itching showed stronger downregulation of Th2 (*IL4R*, *CCL17*), Th1 (*CCL3/4*, *CXCL8*), and Th17 (*CXCL1*, *IL17RA*, *PI3*).

Importantly, improvements in clinical efficacy parameters following nemolizumab treatment were found to be significantly positively correlated with these changes in fibrosis and pruritus markers. Specifically, improvements in EASI and PPNRS scores correlated significantly with the changes in Th17, fibrosis, skin barrier, pruritus, and lipid biomarkers amongst all nemolizumab-treated patients and those with severe itch at baseline (Figure 2).

Table 1: Overall summary of treatment-emergent adverse events during treatment period.

	PNE (N=962)	NN (N=536)
AEs or SAEs, n (%)		
Any TEAE	659 (68.5)	362 (67.5)
Any TEAE related to study drug	178 (18.5)	101 (18.8)
Any serious TEAE	51 (5.3)	19 (3.5)
Any serious TEAE related to study drug	7 (0.7)	1 (0.2)
Any TEAE leading to temporary discontinuation of study drug, n (%)	107 (11.1)	53 (9.9)
Any TEAE leading to permanent discontinuation of study drug, n (%)	30 (3.1)	21 (3.9)
Any TEAE leading to permanent discontinuation from study, n (%)	29 (3.0)	19 (3.5)
Any severe TEAE, n (%)	51 (5.3)	23 (4.3)
AESI, n (%)		
Infections	214 (22.2)	119 (22.2)
Newly diagnosed asthma or worsening of asthma (post-adjudication by IAC)	46 (4.8)	25 (4.7)
Peripheral oedema: limbs, bilateral; facial oedema	8 (0.8)	9 (1.7)
Injection-related reactions*	1 (0.1)	0
Elevated ALT or AST (>3x ULN) in combination with elevated bilirubin (>2x ULN)	0	1 (0.2)
TEAEs ≥5% (MedDRA Preferred Term), n (%)		
COVID-19	173 (18.0)	92 (17.2)
Nasopharyngitis	95 (9.9)	58 (10.8)
Upper respiratory tract infection	64 (6.7)	31 (5.8)
Headache	48 (5.0)	25 (4.7)
Dermatitis atopic	132 (13.7)	78 (14.6)

*Injection-related reactions include anaphylactic reactions, acute allergic reactions requiring treatment, and severe injection site reactions with a duration of >24 hours.

AE: adverse event; AESI: adverse event of special interest; ALT: alanine transaminase; AST: aspartate transaminase; IAC: independent adjudication committee; MedDRA: Medical Dictionary for Regulatory Activities; N: total number of patients in treatment group in the safety population; n: number of patients with available data; NN: nemolizumab naïve; PNE: previous nemolizumab experience; SAE: serious adverse event; TEAE: treatment-emergent adverse event; ULN: upper limit of normal.

Figure 2: Improvements in Eczema Area and Severity Index and Peak Pruritus Numerical Rating Scale following nemolizumab correlate with changes in fibrosis, pruritus endocrine disrupting chemicals/cholesterol esters lipids, and skin barrier markers.

All nemolizumab patients

EASI			PPNRS		
Biomarker	R	p	Biomarker	R	p
UBE2G2	0.35	0.000	CHD8	0.31	0.003
BRD9	0.33	0.000	KDM4B	0.29	0.006
ABHD12	0.33	0.001	NIPA2	0.28	0.007
MNT	0.31	0.001	ISCA1	0.37	0.000
SREBF1	0.30	0.001	NSD3	0.36	0.000
AP5Z1	0.30	0.002	YIPF3	0.36	0.000
ATP2B4	0.30	0.002	PRPF18	0.35	0.001
POLE	0.29	0.002	NFATC3	0.34	0.001
SUPT6H	0.28	0.004	BAZ2A	0.34	0.001
SCRIB	0.27	0.004	BRAP	0.33	0.001
CRAMP1	0.26	0.007	DDX46	0.33	0.001
CCDC85C	0.25	0.008	POLR2J	0.33	0.002
PEAK1	0.25	0.008	NKIRAS2	0.33	0.002

Nemolizumab with severe itch

EASI			PPNRS		
Biomarker	R	p	Biomarker	R	p
ZNF83	0.58	0.001	IGF1R	0.51	0.003
PEAK1	0.57	0.001	WAPL	0.48	0.006
UBE2G2	0.55	0.001	SMYD2	0.47	0.008
DNAJC3-DT	0.53	0.001	CD55	0.48	0.006
ASNS	0.52	0.001	F2RL1	0.60	0.000
SREBF1	0.51	0.001	CRB3	0.52	0.003
RNF123	0.50	0.001	EMP1	0.47	0.008
SF3A2	0.50	0.001	PTPRK	0.47	0.008
NGRN	0.48	0.001	NFATC3	0.57	0.001
ACVR1B	0.41	0.01	SELENOI	0.56	0.001
TBC1D2B	0.41	0.01	KLHL28	0.55	0.001
CRTAP	0.41	0.011	LINC00592	0.54	0.002
MTURN	0.41	0.011	JTB	0.53	0.002
			CRY1	0.53	0.002
			ZNRF2	0.52	0.003
			HES1	0.52	0.003

All nemolizumab patients

EASI			PPNRS		
Biomarker	R	p	Biomarker	R	p
SNORA71A	-0.32	0.001	FLCN	-0.32	0.002
CD302	-0.31	0.001	NPHP4	-0.27	0.008
BAG4	-0.30	0.002	PRX	-0.25	0.017
NSUN6	-0.29	0.002	FZR1	-0.31	0.003
YWHAZ	-0.29	0.002	APC2	-0.31	0.003
CDC42	-0.26	0.006	TYW1	-0.29	0.005
MASTL	-0.26	0.007	C17orf58	-0.29	0.005
FBXO33	-0.25	0.008	GHRLOS	-0.29	0.006
TMEM120A	-0.25	0.009	DUOX2	-0.25	0.018
SERPING1	-0.25	0.010	FES	-0.25	0.018
PELI1	-0.24	0.010	EVC	-0.28	0.007
SCARNA12	-0.24	0.012	SRSF7	-0.28	0.007
SCARNA22	-0.24	0.013	TRAF2	-0.28	0.008
SLC31A2	-0.23	0.014	EML2	-0.28	0.008
CD180	-0.23	0.015	MRNIP	-0.27	0.009

Nemolizumab with severe itch

EASI			PPNRS		
Biomarker	R	p	Biomarker	R	p
ATP5MK	-0.53	0.0006	IRF3	-0.47	0.007
ARL6IP5	-0.53	0.0006	STARD3	-0.48	0.006
FBXO33	-0.50	0.0012	MPP3	-0.49	0.005
C1orf52	-0.50	0.0012	ZNF513	-0.46	0.009
RHOA	-0.48	0.0021	ZNF296	-0.41	0.022
CSTB	-0.48	0.0022	WDR6	-0.46	0.009
SYMPK	-0.41	0.011	USP28	-0.42	0.018
ZNF710	-0.41	0.0111	TYW1	-0.50	0.004
ZCCHC3	-0.40	0.0125	TAF4	-0.46	0.009
RHOQ	-0.40	0.0127	SNAI3	-0.46	0.010
TRAF3	-0.47	0.0027	SETDB2	-0.57	0.001
PLPP5	-0.47	0.003	SENP3	-0.42	0.019
ACLY	-0.38	0.0178	RUFY1	-0.43	0.016
			RFPL4AP4	-0.42	0.019
			RASAL2	-0.44	0.013
			PRPSAP1	-0.51	0.004
			PLCB3	-0.43	0.016

■ Pruritus ■ Fibrosis ■ EDC/CE Lipids ■ Skin Barrier

EASI: Eczema Area and Severity Index; PPNRS: Peak Pruritus Numerical Rating Scale.

Overall, these study findings show that nemolizumab exerts a robust impact on pruritus and hyperplasia/fibrosis biomarkers which correlate with clinical improvements in itch, skin, and QoL in

patients with AD. The greater immune modulation in patients with severe pruritus highlights nemolizumab's potential in patients with AD heavily impacted by itch, Guttman-Yassky concluded.

References

1. Plant A, Arden-Jones M. Advances in atopic dermatitis. *Clin Med (Lond)*. 2021;21(3):177-81.
2. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. *Ann Dermatol*. 2012;24(3):253-60.
3. Weidinger S et al. Atopic dermatitis. *Nat Rev Dis Primers*. 2018;4(1):1.
4. Nemoto O et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. *Br J Dermatol*. 2016;174(2):296-304.
5. Facheris P et al. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. *Cell Mol Immunol*. 2023;20(5):448-74.
6. Datsi A et al. Interleukin-31: the "itchy" cytokine in inflammation and therapy. *Allergy*. 2021;76(10):2982-97.
7. Kato A et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. *J Dermatol Sci*. 2014;74(3):229-35.
8. Dillon SR et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. *Nat Immunol*. 2004;5(7):752-60.
9. Silverberg JI et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. *Lancet*. 2024;404(10451):445-60.
10. Thaçi D et al. Nemolizumab long-term safety and efficacy up to 56 weeks in ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Oral presentation D1T01.1D. EADV Congress, 25-28 September, 2024.
11. Clinicaltrials.gov. Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis. Available at: <https://clinicaltrials.gov/study/NCT03989206> Last accessed: 4 Dec 2024.
12. Guttman-Yassky E et al. Tape-strips transcriptomic analysis from patients with moderate to severe atopic dermatitis treated with nemolizumab. Oral presentation D1T01.2C. EADV Congress, 25-28 September, 2024.
13. Dyjack N et al. Minimally invasive skin tape strip RNA-seq identifies novel characteristics of type 2-high atopic dermatitis disease endotype. *Allergy Clin Immunol*. 2018;6;141(4):1298-309.